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ABSTRACT: As part of the International Cooperative
Biodiversity Groups (ICBG) Program, we were interested in
identifying biologically active unfolded protein response
(UPR) inducing compounds from marine microorganisms
isolated from Costa Rican biota. With this aim in mind we have
now generated more than 33,000 unique prefractionated
natural product extracts from marine and terrestrial organisms
that have been submitted to the Center of Chemical Genomics
(CCG) at the University of Michigan for high throughput
screening (HTS). An eﬀective complementary cell-based assay
to identify novel modulators of UPR signaling was used for screening extracts. Active fractions were iteratively subjected to
reverse-phase HPLC chromatographic analysis, and together with lobophorin A, B, E, and F (1−4), three new lobophorin
congeners, designated as CR1 (5), CR2 (6), and CR3 (7) were isolated. Herein, we report that secondary assays revealed that the
new lobophorins induced UPR-associated gene expression, inhibited oral squamous cell carcinoma cell growth, and led to UPR-
dependent cell death in murine embryonic ﬁbroblast (MEF) cells.
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In 2011 there were nearly 300,000 Americans living with oralor pharyngeal cancer and 40,000 new cases are expected this
year.1 Late stage diagnosis and a paucity of new therapies have
stagnated the ﬁve-year survival rate at less than 50%; and the
serendipitous discovery of cisplatin almost 40 years ago
provided one of the last major improvements in our ability to
treat these patients.
Approximately 60% of the drugs currently on the market are
derived from natural product sources.2 Since many bioactive
metabolites initially isolated from invertebrates are biosynthe-
sized by associated microorganisms, it is often not possible to
obtain culturable species that produce suﬃcient biomass for
compound isolation and identiﬁcation. With only 0.001−0.1%
of marine microorganisms identiﬁed, however, they represent a
relatively unexplored source of potential bioactive compounds.3
The collection of natural products into screenable libraries and
the development of reliable novel target assays for HTS is
essential to ﬁnd new active structures as well as to identify new
activities for known compounds.
In our ongoing eﬀort to identify novel compounds that
activate the apoptotic arm of unfolded protein response (UPR)
as a potential anticancer strategy (Figure 1), we screened a
collection of natural product extracts at the University of
Michigan Center for Chemical Genomics to identify those that
activated UPR (luciferase) reporters.4 The UPR is a
coordinated response to the accumulation of misfolded protein
in the lumen of the endoplasmic reticulum (ER). Inositol-
requiring enzyme 1 alpha (IRE1α), activating transcription
factor 6 (ATF6), and protein kinase RNA-like endoplasmic
reticulum kinase (PERK) are ER transmembrane sensors that
monitor the productivity of protein folding in the lumen. When
the ability of the ER to properly fold peptides is outpaced by
the demand for new proteins, the UPR is initiated by
genetically distinct pathways that attempt to enhance the
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dynamics of peptide processing (adaptive arm) or lead to cell
death (apoptotic arm) if the challenge is prolonged.5 The
adaptive response is characterized by the unconventional
splicing of a 26 base intron from X-box binding protein
(XBP1) mRNA by IRE1α in the cytoplasm. Spliced XBP1
encodes a multitarget transcription factor that drives the
expression of chaperones, heat shock factors, and other
enzymes that return to the ER to enhance folding. Inhibition
of protein translation, a hallmark of ER stress, occurs via PERK
mediated phosphorylation of eukaryotic initiation factor 2 alpha
(eIF2α). eIF2α phosphorylation also leads to the accumulation
of the proapoptotic transcription factors ATF4 and CHOP.6,7
Given the highly secretory nature of many solid and
hematological tumors it is not surprising that increased
expression of translation factors and high basal levels of stress
and UPR signaling characterize many human cancers. Recent
studies have revealed that more than a dozen human cancers
display increased expression of eukaryotic initiation factors
including breast,8 pancreas, lymphoma, leukemia, and head and
neck squamous cell carcinoma.9,10 As malignant cell popula-
tions begin to grow and invade host tissue, the extracellular
tumor milieu becomes increasingly starved of oxygen, glucose,
and other essential nutrients. Survival in these harsh conditions
requires further UPR activation. We hypothesize that
pharmacologic enforcement of the UPR might overwhelm the
adaptive response in malignant cells and divert them toward
apoptosis, while healthy adjacent cells might see the challenge,
mount an eﬀective adaptive UPR, and return to homeostasis.
A cell-based HTS was engineered using Chinese Hamster
Ovary (CHO) cells stably transfected with luciferase reporters
to speciﬁcally monitor XBP1 splicing or Chop promoter
activation.11 With the goal of identifying new active structures
from renewable marine microbial sources, a collection of 5036
extracts derived from cultivable marine microorganisms was
prepared in collaboration with the National Institute for
Biodiversity (INBio) in Costa Rica. Lobophorins E, F, and
CR1−3 were identiﬁed in a DMSO extract that could
signiﬁcantly activate a Chop-luciferase reporter but not an
XBP1-luciferase reporter (Figure S1), suggesting that one or
more compounds could selectively activate the apoptotic arm of
the UPR. Bioassay guided fractionation of extracts prepared
from the active strain 7790_N4 allowed for the isolation of the
spirotetronate macrolides lobophorin A, B, E, and F (1−4)12,13
and three new congeners designated CR1 (5), CR2 (6), and
CR3 (7) (Figure 2).
Lobophorin CR1 (5) was isolated as a white powder. Its
molecular formula was established by HREIMS as C61H92NO20
(m/z 1180.5993 [M + Na]+; calcd for C61H92NO20Na,
1180.6032), requiring 17 degrees of unsaturation and one
more amu than compound 1 (C61H91N2O19).
Comparison of 1H NMR spectra of compound 5 with 1 did
not reveal a clear diﬀerence. COSY, HSQC, and HMBC data
correlated to (not with) the same signals represented by the
aglycone and trisaccharide moieties that were present in 1.
Diﬀerences between 1 and 5 were identiﬁed in a group of
signals corresponding with the amino sugar. In this group,
together with two methines (δH/δC 4.67/98.4, 3.25/57.4), one
methylene (δH/δC 1.50,1.68/39.3), three methyls (δH/δC 1.07/
16.1, 1.16/26.9, 3.63/51.4), and one quaternary carbon (δC
158.4) showing the same shifts as 1 appeared a new quaternary
carbon at δC 71.5 instead of at δC 52.4 or 91.0 as in lobophorin
A (1) and B (2), respectively. These data indicated that instead
of a nitro or amino group at position D-3, there must be a
hydroxyl group, maintaining the same conﬁguration β as in 1
and 2. All of these data are consistent with the structure of
compound 5 (Table S1 and Figures S2−S7).
The molecular formula of lobophorin CR2 (6), isolated as a
white powder, was established as C61H90N2O22 by HREIMS
(m/z 1247.5697 [M − H + 2Na]+; calcd for C61H89N2O22Na2,
1247.5702), indicating one less degree of unsaturation and 16
more amu than 2. NMR data showed the presence of the same
sugars, three digitoxose and one kijanose, as lobophorin B.
However, some interesting diﬀerences regarding the aglycone
moiety were observed in the 1H and 13C NMR shifts when
compared with the other congeners. Two new signals were
present in the HSQC, an oleﬁnic methylene (δH/δC 4.78, 5.10/
114.0) and an oxymethine (δH/δC 4.06/67.9). These data
together with the lack of the oleﬁnic methine at C-15
(characteristic of lobophorin family) as well as the shift of
methylene C-16 from δH 2.16, 2.49/32.3 in 2, to δH 1.80, 1.91
in 6, suggested the presence of an exocyclic double bond at C-
14 and a hydroxyl group bonded to the methine C-15. COSY
experiment allowed connecting the methine C-15 with the
methylene C-16 through a H−H correlation between H-15 (δH
4.06) and H-16a (δH 1.80). Finally, the exocyclic methylene
was placed at C-14 by HMBC correlations of H-30a (δH 4.78)
with C-13 (δC 45.4) and C-15 (δC 67.9). These data enabled us
to propose the structure of CR2 (see Figure 2), which was
supported by a key ROESY cross peak between H-30a (δH
4.78) and H2-16 (δH16a 1.80 and δH16b 1.91) (Table S2 and
Figure 1. General model of ER stress and the UPR in cancer.
Figure 2. Structure of known lobophorins and novel congeners CR1−
CR3.
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Figures S8−S12). Insuﬃcient CR2 was isolated to obtain
reliable 13C NMR.
Lobophorin CR3 (7) was obtained as a white powder, with
the molecular formula C61H90N2O23 on the basis of its
HREIMS (m/z 1241.5809 [M + Na]+; calcd for
C61H90N2O23, 1241.5832), having the same number of degrees
of unsaturation as 6 and 16 additional amu. After an exhaustive
comparison of all 1H and 13C NMR shifts of 7 with those
present in 6, only one diﬀerence was observed. Carbon C-15
shifted downﬁeld from δC 67.9 to δC 81.0, which can only be
explained by the presence of a hydroperoxyl group at C-15
instead of the hydroxyl (Figure 2 and Table S3 and Figures
S13−S18).
The lobophorin family is related to kijanimicin,14,15 a
spirotetronate antibiotic that is formed by a pentacyclic core
bearing four L-digitoxoses and one nitrosugar. Lobophorins A
(1), B (2), and E (3) have three L-digitoxose units instead of
four, while lobophorin F (4) bears just two. Versipelostatin,
also derived from Streptomyces sp., also has a structure very
similar to the lobophorins and has been reported to activate the
UPR.16,17 Although antimicrobial and antitumor activities have
been reported for kijanimicin18 and lobophorins,13,19−23 herein
we report the ability of lobophorins A, B, E, F, and CR1 (1−5)
to activate the UPR and cell death in two human oral squamous
cell carcinoma (OSCC) cell lines.
The ﬂoor of mouth OSCC cell lines UMSCC1 and
UMSCC14A and nonmalignant primary human epidermal
keratinocytes (nHEK) were treated with lobophorins A, B, E, F,
and CR-1 (1.25−80 μM) for 24 and 48 h. Suﬃcient quantities
of CR-2 and CR-3 were not obtained for inclusion in these
analyses. Lobophorins B, E, F, and CR1 demonstrated the most
potent eﬀects on cell growth (Figure 3A and Table S4A,B).
None of the lobophorins could reduce proliferation of the
nonmalignant cells by 50% at 24 h and only lobophorins B and
F could at 48 h. Next, attention was focused toward
determining whether lobophorin F, one of the most potent
congeners isolated, could induce markers of the UPR.
UMSCC1, UMSCC14A, and UMSC23 cells were treated for
6 or 12 h. qRT-PCR analysis of cDNA pools generated from
whole cell lysates revealed an accumulation of transcripts for
CHOP, spliced XBP1 (XBP1s), GADD34, ATF3, and BiP/
GRP78 (Figures 3B,C and S19). These data indicate that
lobophorins activate the UPR and have signiﬁcant antiprolifer-
ative selectively toward malignant cells.
Having observed lobophorin activated biomarkers of the
UPR and inhibited OSCC growth, Atf4 −/−, Chop −/−, and
eIF2-α (Ser51Ala) mutant murine embryonic ﬁbroblasts
(MEF) and wildtype littermate controls were utilized to
determine at what level the UPR might regulate these eﬀects.
Atf4 null (Figure 4A) and Chop null (Figure 4B) cells were
signiﬁcantly and substantially protected in a dose response
fashion, from lobophorin F after 16 h; Two-way ANOVA, p <
0.0001 for dose and interaction for wildtype vs null (Atf4 and
Chop). Lobophorin B was not appreciably toxic in MEF
cultures under any of the conditions examined (data not
shown). These results indicate lobophorin F is more cytostatic
than lobophorin B, and its ability to inhibit proliferation in
MEF depends on intact Atf4 and Chop. Since the eIF2-α-Atf4-
Chop axis is a well-characterized cornerstone of apoptotic UPR
signaling, cDNA libraries generated from lobophorin F treated
Atf4 null and eIF2-α mutant cells were interrogated for the
accumulation of UPR and cell death transcripts. Lobophorin F-
resistant Atf4-null cells failed to accumulate apoptotic mRNA
transcripts for Noxa, Puma, and Trb3 after 6 h (Figure 4C).
This is a strong indication that the observed reduction of
proliferation in wild type MEF cells was the result of apoptosis.
MEFs with an eIF2-α Ser51Ala knock-in mutation that cannot
phosphorylate eIF2-α or activate Atf4 during ER stress were
similarly unable to up-regulate Noxa, Puma, or Trb3 (Figure
4D). Similar results were obtained in identical experiments
performed with lobophorin B (Figure S20A,B). Considered
together, these data indicate that an intact eIF2-α-Atf4-Chop
signaling is essential for lobophorin to induce apoptosis and
inhibit MEF proliferation.
Herein we have discussed the discovery of ﬁve congeners of
lobophorin in bacterial cultures from marine sediments
collected in Costa Rica. While our studies were underway
two of these lobophorins were reported elsewhere and named
Figure 3. ATP-based luminescent proliferation assays with OSCC and
normal keratinocytes (nHEK) treated with lobophorins. (A) Two-way
ANOVA: OSCC vs nHEK, p < 0.0001 for dose and interaction (Table
S4). qRT-PCR analysis of UPR transcripts in UMSCC14A (B) and
UMSCC23 (C) treated with 40 μM lobophorin F 4 or 2.5 μg/mL
tunicamycin (Tm).
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lobophorin E and F. The three new lobophorins have been
named CR 1−3 to denote they were discovered in Costa Rica.
Lobophorins are structurally similar to the kijanimicin, trierixin,
and versipelostatin. The ability of lobophorin, kijanimicin, and
versipelostatin to inhibit cancer cell growth is known, and
versipelostatin has been reported to activate the UPR. Trierixin,
however, was demonstrated to inhibit markers of the UPR, and
its eﬀect on cancer cell growth is unknown.
Lobophorins E, F, and CR 1−3 were identiﬁed in a DMSO
extract that could signiﬁcantly activate a Chop-luciferase
reporter but not an XBP1-luciferase reporter. Puriﬁed
lobophorins recapitulated this ﬁnding by potently inducing
CHOP gene expression and only modestly splicing XBP1.
Though relatively high concentrations of lobophorins are
required to activate the UPR and interfere with cancer cell
growth it is encouraging that these compounds preferentially
activated the apoptotic arm of the UPR. Studies currently
underway are focused to increase the cultivatable lobophorin in
culture and to elucidate the mechanism by which active
congeners activate the UPR.
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